| Bioactivity | TA-1801 is a hypolipidemic agent. |
| Invitro | TA-1801 inhibits platelet aggregation in vitro[1]. |
| In Vivo | TA-1801 reduces serum cholesterol and triglyceride levels by 23% and 35%, respectively, at a dose of 0.05% in a diet in normal rats, and it is about 10 times more active in hereditary hyperlipidemic rats (THLR/1) than in normal rats[1]. |
| Name | TA-1801 |
| CAS | 88352-44-7 |
| Formula | C17H14ClNO4 |
| Molar Mass | 331.75 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Moriya T, et al. Synthesis of ethyl 2-(4-chlorophenyl)-5-(2-furyl)-4-oxazoleacetate, a hypolipidemic agent, and related compounds. J Med Chem. 1988 Jun;31(6):1197-204. |